In this article4
If you use a continuous glucose monitor or test strips and your Medicare claim came back denied, you're running into one of the most error-prone corners of the entire Medicare program. CMS reminded suppliers in August 2026 that the improper payment rate for glucose monitors was 25.2 percent — roughly one in four claims — with a projected $278.5 million in improper payments in the 2024 reporting period. Separately, the HHS Inspector General found Medicare has been paying suppliers far more for continuous glucose monitor supplies than they cost, and people with Medicare pay 20 percent of those prices. Both problems are being addressed, and both affect what you pay. Here's what's happening and what to do if your claim was denied.
📋Quick Summary
- The improper payment rate for Medicare glucose monitors is 25.2%, totaling a projected $278.5 million in one reporting year.
- Most of these errors are documentation problems, not fraud — 67.6% had no documentation at all, and 26.6% had insufficient documentation.
- Separately, an HHS Inspector General report found Medicare paid suppliers $377 million (69%) more than their acquisition costs for CGMs and supplies over one year.
- Because you pay 20% coinsurance on durable medical equipment, inflated prices meant you were overpaying too.
- CMS has added CGMs to the next round of competitive bidding, which begins January 1, 2028.
- Most denied claims are correctable — the fix usually involves your prescribing doctor's documentation, not you.
Why Glucose Monitor Claims Get Denied So Often
The 25.2 percent improper payment rate sounds alarming, and in fiscal terms it is — but understanding what's actually driving it changes how you should think about a denial notice.
According to CMS data for the 2024 reporting period, most improper payments for glucose monitors trace back to documentation. Missing documentation entirely accounted for 67.6 percent of improper payments. Insufficient documentation accounted for another 26.6 percent. Other errors made up the remaining 5.8 percent. In other words, roughly 94 percent of the problem is paperwork that either wasn't submitted or wasn't complete enough to show the equipment met Medicare's coverage requirements. An improper payment is an accounting finding about documentation — it is not, by itself, a finding of fraud.
For diabetic testing strips specifically, CMS lists three recurring errors that cause denials: claims submitted without a documented diabetes diagnosis code, claims that overlap with an inpatient hospital stay, and claims that overlap with a skilled nursing facility stay. The overlap denials happen because the facility is responsible for supplies during that stay, so a separately billed supply claim covering the same dates gets denied, even though you did nothing wrong.
This matters because most denials are correctable rather than final. A denial caused by a missing diagnosis code or an incomplete visit note is a fixable administrative problem — one that typically requires your prescribing practitioner's office to supply or correct documentation. If you want the underlying framework first, see how Medicare Parts A, B, C, and D actually work, since durable medical equipment sits under Part B.
Because roughly 94% of glucose monitor payment problems stem from missing or insufficient documentation, the fastest path to resolving a denial is usually your prescribing practitioner's office. Ask them to confirm that your diabetes diagnosis is documented, that you had an in-person or Medicare-approved telehealth visit in the 6 months before the CGM was ordered (and every 6 months since), and that the prescription shows you've been trained to use the device. If a supplier submitted the claim, ask which denial reason came back — that tells the office exactly what's missing.
The Overpayment Problem — and Why It Cost You Money Too
Separate from denials, a federal watchdog report identified a pricing problem that has been costing both Medicare and people with Medicare.
The HHS Office of Inspector General compared what Medicare paid for continuous glucose monitors and supplies with what suppliers paid to acquire them. From July 2022 to June 2023, Medicare payments exceeded suppliers' acquisition costs by $377 million — about 69 percent. Even after counting suppliers' estimated total costs, including overhead, Medicare still paid about $70 million, or 8 percent, more.
The gap was concentrated in supplies — the sensors and transmitters that need regular replacement, and the most common CGM-related Medicare billing. Payments for supplies exceeded acquisition costs by $359 million, and exceeded what the same items sold for at retail by $290 million in one year.
This is where the impact on you becomes direct. For Part B durable medical equipment, you generally pay 20 percent of the Medicare-approved amount after the yearly deductible. When Medicare's payment rate is above market price, your 20 percent share is higher too. You can see how the deductible-then-coinsurance structure works in our 2026 Medicare costs breakdown.
The scale of the spending explains why this drew scrutiny: Medicare Part B payments for CGMs and supplies rose from $109 million in 2018 to $1.3 billion in 2023.
Related Medicare Updates
✅What This Means for You
Sources
- Glucose Monitoring Supplies (Medicare Provider Compliance Tips) — Centers for Medicare & Medicaid Services, Last modified Feb 11, 2026
- MLN Connects Newsletter: August 6, 2026 — Centers for Medicare & Medicaid Services, Aug 6, 2026
- Medicare Payments for Continuous Glucose Monitors and Supplies Exceeded Supplier Costs and Retail Market Prices (OEI-04-23-00430) — HHS Office of Inspector General, Nov 20, 2025
- OIG report finds Medicare overpaying for CGMs and supplies — MedTech Dive (Elise Reuter), Nov 26, 2025
- CMS DMEPOS Competitive Bidding Program redux — DLA Piper, Dec 18, 2025
- Durable medical equipment (DME) coverage — Medicare.gov, Undated, accessed Nov 12, 2026
Explore Further
What's Changing — Competitive Bidding and Lower Prices
The Inspector General recommended that CMS pursue lower payment rates for CGMs and supplies and stop overpayments from improper billing codes — about $7 million in potential overpayments. CMS agreed with both. The coding problem is on the supplier side; it doesn't mean you did anything wrong or owe anything back.
CMS's final rule, effective January 1, 2026, adds continuous glucose monitors and insulin pumps to a new nationwide round of competitive bidding for items delivered to your home. CGMs are also being moved to a monthly rental payment that bundles the device with its supplies; if you already own your device, you can keep using it. Bidding takes place in 2026 and 2027, and the new round begins January 1, 2028, with a six-month transition for people with Medicare.
Competitive bidding lowers prices partly by limiting which suppliers can bill Medicare for those items. Contract suppliers must serve everyone with Medicare in the category, either by shipping to your home or by letting you pick up at a local pharmacy or store. But if your current supplier doesn't win a contract, you may need to switch once the new round starts.
| Improper payment rate, glucose monitors (2024 reporting) | 25.2% |
|---|---|
| Projected improper payment amount | $278.5 million |
| Improper payments from NO documentation | 67.6% |
| Improper payments from insufficient documentation | 26.6% |
| Other errors | 5.8% |
| Medicare payments vs. supplier acquisition cost (1 yr) | $377 million more (69%) |
| Supply payments vs. retail prices | $290 million more in one year |
| Part B CGM spending, 2018 | $109 million |
| Part B CGM spending, 2023 | $1.3 billion |
| Your coinsurance on Part B DME | 20% after the deductible |
| Next competitive bidding round begins | January 1, 2028 |
What to Do Right Now If You Depend on a Glucose Monitor
Whether you're dealing with a denial today or simply want to avoid one, a few concrete steps put you in a stronger position.
Confirm your documentation before your next order. Ask your prescribing practitioner's office to verify that your file shows your diabetes diagnosis, a qualifying in-person or telehealth visit within the required 6 months, and the training note for your device. Confirming them ahead of time is far easier than correcting a denial afterward.
Watch for the overlapping-stay problem. If you've recently been in the hospital or a skilled nursing facility, supply claims covering those same dates can be denied, because the facility is responsible for supplies during the stay. If you have a stay coming up, or just had one, flag it with your supplier ahead of time.
Compare your out-of-pocket cost against retail. Since the Inspector General found Medicare's supply payments ran above retail prices, it can be worth checking what your 20 percent coinsurance costs against the cash price at a pharmacy. Cash purchases don't count toward your Part B deductible, so run the numbers for your own situation.
Finally, watch for the competitive bidding change before 2028. If your current supplier isn't a winning bidder, you'll need to switch — and knowing that in advance prevents a gap in supplies. You can look up approved DME suppliers on Medicare.gov, and a free SHIP counselor in your state can review a denial letter with you at no cost.




